- The FDA and Intellia Therapeutics are preparing a regulatory filing for product approval.
- FDA reviewed protocol amendment and interim safety data for a company's product.
FDA agreed to reduced sample size for a clinical trial involving X4 Pharmaceuticals.
1 report, 1 independent
Updated Sep 8
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA agreed to reduced sample size for a clinical trial involving X4 Pharmaceuticals.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
company
legal entity representing an association of people, whether natural, legal or a mixture of both, with a specific objective
Related events
- Jazz Pharmaceuticals received FDA approval for a drug following positive clinical trial results.
- Adam Fisher was appointed as a director in the FDA's Office of Pharmaceutical Quality.
- EyePoint Pharmaceuticals developed its LUCIA trial program in alignment with the FDA, with enrollment noted in Lugano.
- The FDA has questioned promotional materials related to an investigational drug from Alar Pharmaceuticals.
- Nkarta is seeking protocol amendments for its clinical trials under the FDA.